fetching data ...

POS0260 (2022)
LONG-TERM HUMORAL RESPONSE TO SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASE
K. Tascilar1, D. Simon1, A. Kleyer1, F. Fagni1, G. Krönke1, C. Meder2, P. Dietrich3, T. Orlemann3, T. Kliem3, J. Mößner1, A. M. Liphardt1, V. Schönau1, D. Bohr1, L. Schuster1, F. Hartmann1, J. Taubmann1, M. Leppkes3, A. Ramming1, M. Pachowsky1, F. Schuch4, M. Ronneberger4, S. Kleinert4, A. Hueber5, K. Manger6, B. Manger1, R. Atreya3, C. Berking2, M. Sticherling2, M. F. Neurath3, G. Schett1
1Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3, Erlangen, Germany
2Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany
3Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Department of Internal Medicine 1, Erlangen, Germany
4Rheumatology Clinical Practice, Erlangen, Erlangen, Germany
5Paracelsus University Nürnberg., Clinic for Internal Medicine 5, Nürnberg, Germany
6Rheumatology Practice, Bamberg, Bamberg, Germany

Background: The first vaccine against SARS-CoV-2 was approved in December 2020. Immunogenicity of SARS-CoV2 vaccines in patients with immune-mediated inflammatory disease (IMID) have so far been evaluated in the 2-6 weeks following complete vaccination and risk groups for poor early vaccine response have been identified leading to specific vaccination recommendations. However, data on the long-term course and persistence of vaccine response in IMID patients, as well as the outcomes of the specific recommendations are lacking.


Objectives: To evaluate the long-term course of humoral response to SARS-CoV-2 vaccination in a large prospective cohort of IMID patients and non-IMID controls with a follow-up duration of up-to to 10 months after the first vaccine dose.


Methods: We have initiated a prospective dynamic cohort of IMID patients and healthy controls in February 2020 to monitor immune response to SARS-CoV-2 and respiratory infections including COVID-19 (1). Participants who contributed data starting from the 4 weeks before their first vaccination onwards were included in this analysis. Antibodies against SARS-CoV-2 spike protein were quantified with an ELISA from Euroimmun (Lübeck, Germany) with an optical density cutoff of 0.8. We fitted linear mixed-effect models for log-transformed antibody levels using time splines with adjustment for age and sex. Marginal mean antibody levels with 95% confidence intervals (CI) were estimated at selected time points for IMID patients and controls with double vaccination. We descriptively analyzed the observed antibody levels over time in cohort participants receiving two vaccinations vs. three vaccinations.


Results: Among 5076 cohort participants, 3147 IMID patients and healthy controls (mean (SD) age 49 (16)) provided 4756 samples for this analysis between December 2020 and 2021, with a median (IQR) 28 (14-31) weeks of follow-up after the first vaccination ( Table 1 ). 2965 (94%) participants had received at least 2 and 223 (7%) participants had received three vaccine doses by the date of their latest sampling. In IMID patients, age and sex-adjusted estimated marginal mean antibody levels waned after week 16 and were substantially reduced at all time points compared to the controls, finally dropping to the borderline range (1.01, 95%CI 0.86 to 1.19) at week 40 ( Figure 1A , Table 1 ). A third dose was given to 128 (7%) of IMID patients with a poor response to 2 vaccine doses after a median 20 weeks of the second dose (IQR 10 to 26 weeks). After the third dose, antibody levels in IMID patients were comparable to those of healthy controls at 40 weeks who had three vaccine doses. These were also higher than that of IMID patients and controls who did not receive a third dose ( Figure 1B ).

Participant characteristics and antibody levels

Healthy controls IMID
 N 1199 1948
 Age, mean (SD) 40.8 (13.5) 54.3 (14.8)
 Follow-up, weeks, median (IQR) 31.1 (23.8-36.6) 19.6 (12.3-26.6)
 Follow-up range, weeks, 1.6-46.1 1.7-46.3
Sex, n(%)
 Female 554 (46.2) 1136 (58.3)
Vaccine intervals, ´median (IQR)
 1 st to 2 nd dose 4.6 (3.0-6.0) 6.0 (5.0-6.1)
 2 nd to 3 rd dose 29.6 (26.9-36.4) 19.9 (10.0-26.1)
Diagnosis, n (%)
 Spondyloarthritis - 713 (36.6)
 Rheumatoid arthritis - 489 (25.1)
 Autoimmune disease, systemic+ - 420 (21.5)
 Inflammatory bowel disease - 219 (11.2)
 Psoriasis - 107 (5.5)
Mean* antibody levels after 1 st dose
 Week-8 4.16 (3.89 to 4.45) 2.97 (2.83 to 3.12)
 Week-16 8.39 (7.81 to 9.02) 5.04 (4.81 to 5.28)
 Week-32 5.02 (4.73 to 5.33) 2.52 (2.32 to 2.74)
 Week-40 2.14 (1.95 to 2.35) 1.01 (0.86 to 1.19)

+ Systemic lupus, systemic sclerosis, Sjögren’s syndrome, vasculitis

* Estimated marginal means adjusted for age and sex.


Conclusion: Humoral response to vaccination against SARS-CoV-2 was weaker in IMID patients compared to controls at all time points after the first vaccine dose and practically disappeared after 1 year. IMID patients can still achieve a good antibody response with a third dose even after a weak response with two doses.


REFERENCES:

[1]Simon D et al Nat Commun 2020


Disclosure of Interests: None declared

Citation: , volume 81, supplement 1, year 2022, page 371
Session: Vaccination against SARS-CoV-2 (Poster Tours)